Vaccine Technologies Market By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant, Conjugate and Subunit Vaccines, Toxoid Vaccines, Others), By Delivery Method (Parenteral, Oral, Nasal), By Type (Monovalent Vaccines, Multivalent Vaccines): Global Opportunity Analysis and Industry Forecast, 2024-2033
The vaccine technologies market was valued at $48,460.07 million in 2023 and is estimated to reach $90,573.02 million by 2033, exhibiting a CAGR of 6.4% from 2024 to 2033.
Vaccine technologies encompass the scientific methods and biotechnological approaches employed to develop vaccines that protect against infectious diseases, cancers, and other health conditions. These technologies have evolved significantly over time, progressing from traditional inactivated and live-attenuated vaccines to innovative platforms such as messenger RNA (mRNA) vaccines, viral vector-based vaccines, and protein subunit vaccines. Thus, vaccine technologies play a pivotal role in safeguarding public health and addressing emerging global health challenges.
The global vaccine technologies market is witnessing robust growth due to alarming rise in global burden of infectious diseases such as influenza and hepatitis. As per a study published in 2023 by the World Health Organization, influenza alone causes 3–5 million severe cases annually, highlighting the need for effective vaccines. In addition, increase in governments investments in vaccine research and manufacturing infrastructure to ensure preparedness for pandemics is notably contributing toward the market growth. Rise in public awareness campaigns and global immunization initiatives by organizations like UNICEF and GAVI have boosted vaccine uptake, further encouraging the development of advanced vaccine technologies. Moreover, rise in outbreaks of zoonotic diseases, including Ebola and avian influenza, highlight the need for vaccine technologies capable of addressing emerging threats. For instance, a study by the World Health Organization revealed that over 60% of emerging infectious diseases globally are zoonoses. However, developing advanced vaccine technologies, such as mRNA or viral vector platforms, requires substantial investment in research, clinical trials, and manufacturing infrastructure, which significantly hampers the market growth. While vaccines are generally safe, rare adverse events can erode public confidence and lead to litigation, thus restraining the market growth. For example, common side effects after pneumococcal conjugate vaccination include redness, swelling, pain at the injection site, fever, loss of appetite, irritability, fatigue, headache, muscle or joint pain, and chills. On the contrary, innovations such as mRNA technology, viral vector platforms, and nanotechnology are revolutionizing vaccine design, improving efficacy and safety. Such developments are expected to open new avenues for the expansion of the global market during the forecast period.
The vaccine technologies market is segmented into technology, delivery method, type, and region. By technology, the market is classified into live attenuated vaccines, inactivated vaccines, recombinant, conjugate, and subunit vaccines; toxoid vaccines; and others. Depending on delivery method, it is segregated into parenteral, oral, and nasal. On the basis of type, it is divided into monovalent vaccines and multivalent vaccines. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Competitive Analysis
The key players operating in the vaccine technologies market include Sanofi, Pfizer Inc., Emergent BioSolutions Inc, AstraZeneca, CSL Limited, Sinovac Biotech Ltd., Bavarian Nordic, Chongqing Zhifei Biological Products Co., Ltd., Merck & Co. Inc., GSK Plc., and Bharat Biotech International Limited. These players have adopted product launch, agreement, product approval, and clinical trials their key strategies to strengthen their foothold in the competitive market.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine technologies market analysis from 2023 to 2033 to identify the prevailing vaccine technologies market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the vaccine technologies market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global vaccine technologies market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technology
Live Attenuated Vaccines
Inactivated Vaccines
Recombinant, Conjugate and Subunit Vaccines
Toxoid Vaccines
Others
By Delivery Method
Parenteral
Oral
Nasal
By Type
Monovalent Vaccines
Multivalent Vaccines
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Emergent BioSolutions Inc.
CSL Limited
GSK plc.
Bavarian Nordic
Merck & Co Inc
Pfizer Inc.
Sinovac Biotech Ltd
AstraZeneca
Chongqing Zhifei Biological Products Co., Ltd.
Sanofi
Bharat Biotech International Limited
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of infectious diseases
- 3.4.1.2. Growing trend towards preventive healthcare
- 3.4.1.3. Government Immunization Programs and Initiatives
- 3.4.2. Restraints
- 3.4.2.1. Cold Chain Storage and Logistics Challenges
- 3.4.3. Opportunities
- 3.4.3.1. Technological advancement
- CHAPTER 4: VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Live Attenuated Vaccines
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Inactivated Vaccines
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Recombinant, Conjugate and Subunit Vaccines
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Toxoid Vaccines
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- CHAPTER 5: VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Parenteral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Oral
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Nasal
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: VACCINE TECHNOLOGIES MARKET, BY TYPE
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Monovalent Vaccines
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Multivalent Vaccines
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- CHAPTER 7: VACCINE TECHNOLOGIES MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Technology
- 7.2.3. Market size and forecast, by Delivery Method
- 7.2.4. Market size and forecast, by Type
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Technology
- 7.2.5.1.2. Market size and forecast, by Delivery Method
- 7.2.5.1.3. Market size and forecast, by Type
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Technology
- 7.2.5.2.2. Market size and forecast, by Delivery Method
- 7.2.5.2.3. Market size and forecast, by Type
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Technology
- 7.2.5.3.2. Market size and forecast, by Delivery Method
- 7.2.5.3.3. Market size and forecast, by Type
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Technology
- 7.3.3. Market size and forecast, by Delivery Method
- 7.3.4. Market size and forecast, by Type
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Technology
- 7.3.5.1.2. Market size and forecast, by Delivery Method
- 7.3.5.1.3. Market size and forecast, by Type
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Technology
- 7.3.5.2.2. Market size and forecast, by Delivery Method
- 7.3.5.2.3. Market size and forecast, by Type
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Technology
- 7.3.5.3.2. Market size and forecast, by Delivery Method
- 7.3.5.3.3. Market size and forecast, by Type
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Technology
- 7.3.5.4.2. Market size and forecast, by Delivery Method
- 7.3.5.4.3. Market size and forecast, by Type
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Technology
- 7.3.5.5.2. Market size and forecast, by Delivery Method
- 7.3.5.5.3. Market size and forecast, by Type
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Technology
- 7.3.5.6.2. Market size and forecast, by Delivery Method
- 7.3.5.6.3. Market size and forecast, by Type
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Technology
- 7.4.3. Market size and forecast, by Delivery Method
- 7.4.4. Market size and forecast, by Type
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Technology
- 7.4.5.1.2. Market size and forecast, by Delivery Method
- 7.4.5.1.3. Market size and forecast, by Type
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Technology
- 7.4.5.2.2. Market size and forecast, by Delivery Method
- 7.4.5.2.3. Market size and forecast, by Type
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Technology
- 7.4.5.3.2. Market size and forecast, by Delivery Method
- 7.4.5.3.3. Market size and forecast, by Type
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Technology
- 7.4.5.4.2. Market size and forecast, by Delivery Method
- 7.4.5.4.3. Market size and forecast, by Type
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Technology
- 7.4.5.5.2. Market size and forecast, by Delivery Method
- 7.4.5.5.3. Market size and forecast, by Type
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Technology
- 7.4.5.6.2. Market size and forecast, by Delivery Method
- 7.4.5.6.3. Market size and forecast, by Type
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Technology
- 7.5.3. Market size and forecast, by Delivery Method
- 7.5.4. Market size and forecast, by Type
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Technology
- 7.5.5.1.2. Market size and forecast, by Delivery Method
- 7.5.5.1.3. Market size and forecast, by Type
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Technology
- 7.5.5.2.2. Market size and forecast, by Delivery Method
- 7.5.5.2.3. Market size and forecast, by Type
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Technology
- 7.5.5.3.2. Market size and forecast, by Delivery Method
- 7.5.5.3.3. Market size and forecast, by Type
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Technology
- 7.5.5.4.2. Market size and forecast, by Delivery Method
- 7.5.5.4.3. Market size and forecast, by Type
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Sanofi
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Pfizer Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Emergent BioSolutions Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Bavarian Nordic
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Bharat Biotech International Limited
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Key strategic moves and developments
- 9.6. Chongqing Zhifei Biological Products Co., Ltd.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Sinovac Biotech Ltd
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. AstraZeneca
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. CSL Limited
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. GSK plc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- 9.11. Merck & Co Inc
- 9.11.1. Company overview
- 9.11.2. Key executives
- 9.11.3. Company snapshot
- 9.11.4. Operating business segments
- 9.11.5. Product portfolio
- 9.11.6. Business performance
- 9.11.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 02. VACCINE TECHNOLOGIES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2023-2033 ($MILLION)
- TABLE 03. VACCINE TECHNOLOGIES MARKET FOR INACTIVATED VACCINES, BY REGION, 2023-2033 ($MILLION)
- TABLE 04. VACCINE TECHNOLOGIES MARKET FOR RECOMBINANT, CONJUGATE AND SUBUNIT VACCINES, BY REGION, 2023-2033 ($MILLION)
- TABLE 05. VACCINE TECHNOLOGIES MARKET FOR TOXOID VACCINES, BY REGION, 2023-2033 ($MILLION)
- TABLE 06. VACCINE TECHNOLOGIES MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
- TABLE 07. GLOBAL VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 08. VACCINE TECHNOLOGIES MARKET FOR PARENTERAL, BY REGION, 2023-2033 ($MILLION)
- TABLE 09. VACCINE TECHNOLOGIES MARKET FOR ORAL, BY REGION, 2023-2033 ($MILLION)
- TABLE 10. VACCINE TECHNOLOGIES MARKET FOR NASAL, BY REGION, 2023-2033 ($MILLION)
- TABLE 11. GLOBAL VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 12. VACCINE TECHNOLOGIES MARKET FOR MONOVALENT VACCINES, BY REGION, 2023-2033 ($MILLION)
- TABLE 13. VACCINE TECHNOLOGIES MARKET FOR MULTIVALENT VACCINES, BY REGION, 2023-2033 ($MILLION)
- TABLE 14. VACCINE TECHNOLOGIES MARKET, BY REGION, 2023-2033 ($MILLION)
- TABLE 15. NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 16. NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 17. NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 18. NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 19. U.S. VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 20. U.S. VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 21. U.S. VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 22. CANADA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 23. CANADA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 24. CANADA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 25. MEXICO VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 26. MEXICO VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 27. MEXICO VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 28. EUROPE VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 29. EUROPE VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 30. EUROPE VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 31. EUROPE VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 32. GERMANY VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 33. GERMANY VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 34. GERMANY VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 35. FRANCE VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 36. FRANCE VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 37. FRANCE VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 38. UK VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 39. UK VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 40. UK VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 41. ITALY VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 42. ITALY VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 43. ITALY VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 44. SPAIN VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 45. SPAIN VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 46. SPAIN VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 47. REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 48. REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 49. REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 50. ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 51. ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 52. ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 53. ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 54. JAPAN VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 55. JAPAN VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 56. JAPAN VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 57. CHINA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 58. CHINA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 59. CHINA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 60. INDIA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 61. INDIA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 62. INDIA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 63. AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 64. AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 65. AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 66. SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 67. SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 68. SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 72. LAMEA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 73. LAMEA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 74. LAMEA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 75. LAMEA VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2023-2033 ($MILLION)
- TABLE 76. BRAZIL VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 77. BRAZIL VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 78. BRAZIL VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 79. SAUDI ARABIA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 80. SAUDI ARABIA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 81. SAUDI ARABIA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 82. SOUTH AFRICA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 83. SOUTH AFRICA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 84. SOUTH AFRICA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 85. REST OF LAMEA VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023-2033 ($MILLION)
- TABLE 86. REST OF LAMEA VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023-2033 ($MILLION)
- TABLE 87. REST OF LAMEA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023-2033 ($MILLION)
- TABLE 88. SANOFI: KEY EXECUTIVES
- TABLE 89. SANOFI: COMPANY SNAPSHOT
- TABLE 90. SANOFI: PRODUCT SEGMENTS
- TABLE 91. SANOFI: PRODUCT PORTFOLIO
- TABLE 92. SANOFI: KEY STRATERGIES
- TABLE 93. PFIZER INC.: KEY EXECUTIVES
- TABLE 94. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 95. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 96. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 97. PFIZER INC.: KEY STRATERGIES
- TABLE 98. EMERGENT BIOSOLUTIONS INC.: KEY EXECUTIVES
- TABLE 99. EMERGENT BIOSOLUTIONS INC.: COMPANY SNAPSHOT
- TABLE 100. EMERGENT BIOSOLUTIONS INC.: PRODUCT SEGMENTS
- TABLE 101. EMERGENT BIOSOLUTIONS INC.: PRODUCT PORTFOLIO
- TABLE 102. EMERGENT BIOSOLUTIONS INC.: KEY STRATERGIES
- TABLE 103. BAVARIAN NORDIC: KEY EXECUTIVES
- TABLE 104. BAVARIAN NORDIC: COMPANY SNAPSHOT
- TABLE 105. BAVARIAN NORDIC: PRODUCT SEGMENTS
- TABLE 106. BAVARIAN NORDIC: PRODUCT PORTFOLIO
- TABLE 107. BAVARIAN NORDIC: KEY STRATERGIES
- TABLE 108. BHARAT BIOTECH INTERNATIONAL LIMITED: KEY EXECUTIVES
- TABLE 109. BHARAT BIOTECH INTERNATIONAL LIMITED: COMPANY SNAPSHOT
- TABLE 110. BHARAT BIOTECH INTERNATIONAL LIMITED: PRODUCT SEGMENTS
- TABLE 111. BHARAT BIOTECH INTERNATIONAL LIMITED: PRODUCT PORTFOLIO
- TABLE 112. BHARAT BIOTECH INTERNATIONAL LIMITED: KEY STRATERGIES
- TABLE 113. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: KEY EXECUTIVES
- TABLE 114. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: COMPANY SNAPSHOT
- TABLE 115. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: PRODUCT SEGMENTS
- TABLE 116. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: PRODUCT PORTFOLIO
- TABLE 117. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: KEY STRATERGIES
- TABLE 118. SINOVAC BIOTECH LTD: KEY EXECUTIVES
- TABLE 119. SINOVAC BIOTECH LTD: COMPANY SNAPSHOT
- TABLE 120. SINOVAC BIOTECH LTD: PRODUCT SEGMENTS
- TABLE 121. SINOVAC BIOTECH LTD: PRODUCT PORTFOLIO
- TABLE 122. SINOVAC BIOTECH LTD: KEY STRATERGIES
- TABLE 123. ASTRAZENECA: KEY EXECUTIVES
- TABLE 124. ASTRAZENECA: COMPANY SNAPSHOT
- TABLE 125. ASTRAZENECA: PRODUCT SEGMENTS
- TABLE 126. ASTRAZENECA: PRODUCT PORTFOLIO
- TABLE 127. ASTRAZENECA: KEY STRATERGIES
- TABLE 128. CSL LIMITED: KEY EXECUTIVES
- TABLE 129. CSL LIMITED: COMPANY SNAPSHOT
- TABLE 130. CSL LIMITED: PRODUCT SEGMENTS
- TABLE 131. CSL LIMITED: PRODUCT PORTFOLIO
- TABLE 132. CSL LIMITED: KEY STRATERGIES
- TABLE 133. GSK PLC.: KEY EXECUTIVES
- TABLE 134. GSK PLC.: COMPANY SNAPSHOT
- TABLE 135. GSK PLC.: PRODUCT SEGMENTS
- TABLE 136. GSK PLC.: PRODUCT PORTFOLIO
- TABLE 137. GSK PLC.: KEY STRATERGIES
- TABLE 138. MERCK & CO INC: KEY EXECUTIVES
- TABLE 139. MERCK & CO INC: COMPANY SNAPSHOT
- TABLE 140. MERCK & CO INC: PRODUCT SEGMENTS
- TABLE 141. MERCK & CO INC: PRODUCT PORTFOLIO
- TABLE 142. MERCK & CO INC: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. VACCINE TECHNOLOGIES MARKET, 2023-2033
- FIGURE 02. SEGMENTATION OF VACCINE TECHNOLOGIES MARKET,2023-2033
- FIGURE 03. TOP IMPACTING FACTORS IN VACCINE TECHNOLOGIES MARKET (2023 TO 2033)
- FIGURE 04. TOP INVESTMENT POCKETS IN VACCINE TECHNOLOGIES MARKET (2024-2033)
- FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 07. MODERATE THREAT OF SUBSTITUTES
- FIGURE 08. MODERATE INTENSITY OF RIVALRY
- FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL VACCINE TECHNOLOGIES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023 AND 2033(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR INACTIVATED VACCINES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR RECOMBINANT, CONJUGATE AND SUBUNIT VACCINES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR TOXOID VACCINES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
- FIGURE 17. VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD, 2023 AND 2033(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR PARENTERAL, BY COUNTRY 2023 AND 2033(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR ORAL, BY COUNTRY 2023 AND 2033(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR NASAL, BY COUNTRY 2023 AND 2033(%)
- FIGURE 21. VACCINE TECHNOLOGIES MARKET, BY TYPE, 2023 AND 2033(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR MONOVALENT VACCINES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 23. COMPARATIVE SHARE ANALYSIS OF VACCINE TECHNOLOGIES MARKET FOR MULTIVALENT VACCINES, BY COUNTRY 2023 AND 2033(%)
- FIGURE 24. VACCINE TECHNOLOGIES MARKET BY REGION, 2023 AND 2033(%)
- FIGURE 25. U.S. VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 26. CANADA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 27. MEXICO VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 28. GERMANY VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 29. FRANCE VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 30. UK VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 31. ITALY VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 32. SPAIN VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 33. REST OF EUROPE VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 34. JAPAN VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 35. CHINA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 36. INDIA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 37. AUSTRALIA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 38. SOUTH KOREA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 39. REST OF ASIA-PACIFIC VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 40. BRAZIL VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 41. SAUDI ARABIA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 42. SOUTH AFRICA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 43. REST OF LAMEA VACCINE TECHNOLOGIES MARKET, 2023-2033 ($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR (2021-2024)
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2024)
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY (2021-2024)
- FIGURE 47. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48. COMPETITIVE DASHBOARD
- FIGURE 49. COMPETITIVE HEATMAP: VACCINE TECHNOLOGIES MARKET
- FIGURE 50. TOP PLAYER POSITIONING, 2023
- FIGURE 51. SANOFI: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 52. SANOFI: REVENUE SHARE BY SEGMENT, 2023 (%)
- FIGURE 53. SANOFI: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 54. PFIZER INC.: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 55. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
- FIGURE 56. PFIZER INC.: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 57. EMERGENT BIOSOLUTIONS INC.: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 58. EMERGENT BIOSOLUTIONS INC.: REVENUE SHARE BY SEGMENT, 2023 (%)
- FIGURE 59. BAVARIAN NORDIC: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 60. CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 61. SINOVAC BIOTECH LTD: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 62. SINOVAC BIOTECH LTD: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 63. ASTRAZENECA: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 64. ASTRAZENECA: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 65. CSL LIMITED: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 66. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2023 (%)
- FIGURE 67. CSL LIMITED: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 68. GSK PLC.: NET REVENUE, 2021-2023 ($MILLION)
- FIGURE 69. GSK PLC.: REVENUE SHARE BY REGION, 2023 (%)
- FIGURE 70. MERCK & CO INC: NET SALES, 2021-2023 ($MILLION)
- FIGURE 71. MERCK & CO INC: REVENUE SHARE BY SEGMENT, 2023 (%)
- FIGURE 72. MERCK & CO INC: REVENUE SHARE BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook